The issuance of a CRL by the FDA typically indicates that the agency requires more information before it can approve a drug. This can lead to delays in the drug's approval process, potentially impacting the company's revenue projections and investor sentiment. The specific concerns raised about CMC and immunogenicity suggest that Theratechnologies will need to conduct additional work to satisfy the FDA's requirements, which could be both time-consuming and costly.